Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Trung Tran

Internal Medicine Gretna, LA Medical Doctor

NPI 1043638893 CMS profile 3679983

120 Ochsner Blvd Ste 470, Gretna, LA 70056

Open in the dashboard

General payments

$5,697

214 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Trung Tran of Gretna, LA is reported in the CMS Open Payments database as having received $5,697 across 214 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,352 53
2024 General $1,022 58
2023 General $1,222 54
2022 General $710 31
2021 General $451 8
2020 General $248 4
2019 General $693 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Trung Tran
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Trung Tran were reported at $1,352. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Trung Tran Internal Medicine median Middle half National median
2019 $693 $159 $48–$570 $163
2020 $248 $119 $33–$402 $114
2021 $451 $135 $37–$521 $132
2022 $710 $141 $42–$496 $149
2023 $1,222 $149 $45–$519 $160
2024 $1,022 $154 $47–$537 $164
2025 $1,352 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Dexcom, Inc. $1,443 29 payments
  2. Novo Nordisk Inc $1,182 62 payments
  3. Lilly USA, LLC $917 42 payments
  4. Abbott Laboratories $476 19 payments
  5. Insulet Corporation $291 8 payments
  6. Amgen Inc. $259 7 payments
  7. Janssen Pharmaceuticals, Inc $207 2 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $171 8 payments
  9. AstraZeneca Pharmaceuticals LP $160 10 payments
  10. Sanofi-Aventis U.S. LLC $116 6 payments
  11. Other $475 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,685 213 payments
  2. Education $12 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $1,040 60 payments
  2. RYBELSUS $829 54 payments
  3. Dexcom G6 Transmitter Endocrinology $763 21 payments
  4. MOUNJARO $478 21 payments
  5. FreeStyle Libre 3 $439 17 payments
  6. DEXCOM G6 TRANSMITTER Endocrinology $319 5 payments
  7. Omnipod $291 8 payments
  8. JARDIANCE $238 13 payments
  9. EVENITY $236 6 payments
  10. DEXCOM CGM $236 2 payments
  11. Other $1,855 76 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 62 drugs

Part D claims

4,498

Median for Endocrinology: 1,959

Drug cost

$2,285,768

Median for Endocrinology: $890,201

Branded share of claims

72%

Median for Endocrinology: 57%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 388 $541,835
Mounjaro Tirzepatide Brand 378 $531,480
Trulicity Dulaglutide Brand 223 $326,411
Jardiance Empagliflozin Brand 194 $215,836
Januvia Sitagliptin Phosphate Brand 53 $71,933
Forteo Teriparatide Brand 12 $57,196
Novolog Flexpen Insulin Aspart Brand 181 $48,821
Tradjenta Linagliptin Brand 39 $43,741
Fiasp Insulin Aspart (Niacinamide) Brand 18 $32,664
Humulin R U-500 Kwikpen Insulin Regular, Human Brand 24 $32,086

The 10 drugs with the highest cost, of 62 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 6,527 Part D prescribers listed as Endocrinology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$25,876

Medicare's payments for the services billed

Medicare patients

198

Average age 70

Services billed

394

150 women, 48 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 52%
Arthritis 47%
Osteoporosis 40%
Chronic kidney disease 36%
Ischemic heart disease 26%
Depression 25%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBELSUS
  • Novo Nordisk Inc $120
$120 — —
Ozempic
  • Novo Nordisk Inc $120
$120 388 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $110
$110 18 —
JARDIANCE
  • Lilly USA, LLC $105
$105 194 —
MOUNJARO
  • Lilly USA, LLC $69
$69 378 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

214 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record